•
Mar 31, 2020

AMN Healthcare Q1 2020 Earnings Report

AMN Healthcare's Q1 2020 results were announced, revealing a revenue increase of 13% year-over-year, driven by organic growth and acquisitions, but net income decreased due to COVID-19 impacts and increased SG&A expenses.

Key Takeaways

AMN Healthcare reported Q1 2020 revenue of $602 million, a 13% increase year-over-year. GAAP EPS was $0.27, while adjusted EPS was $0.79. The company experienced growth in most business lines during the first two months of the year, but the COVID-19 pandemic negatively impacted several divisions in March. The acquisition of Stratus Video contributed $14 million in revenue.

Revenue increased by 13% year-over-year to $602 million, with organic revenue up by 3%.

GAAP EPS decreased to $0.27, while adjusted EPS increased to $0.79.

COVID-19 negatively impacted most divisions except Travel Nurse and VMS in the latter part of the quarter.

Stratus Video acquisition contributed $14 million in revenue, slightly below expectations due to COVID-19.

Total Revenue
$602M
Previous year: $532M
+13.2%
EPS
$0.79
Previous year: $0.75
+5.3%
Gross Profit
$202M
Previous year: $177M
+14.3%
Cash and Equivalents
$98M
Previous year: $19.1M
+412.7%
Free Cash Flow
$37.8M
Previous year: $28.8M
+31.1%
Total Assets
$2.46B
Previous year: $1.64B
+50.2%

AMN Healthcare

AMN Healthcare

AMN Healthcare Revenue by Segment

Forward Guidance

AMN Healthcare projects second quarter revenue to be in the range of $550 million to $570 million. The company has taken steps to reduce spending, decreasing SG&A by approximately 15% on an annualized basis. Second quarter operating margin is expected to be above 6%, and adjusted EBITDA margin is expected to be above 12%.

Positive Outlook

  • Nurse and Allied Solutions segment revenue is expected to be above prior year by 7-10%.
  • Higher travel nurse revenue is anticipated.
  • Revenue for Physician and Leadership Solutions and Technology and Workforce Solutions segments has stabilized.
  • Demand is expected to grow from current levels for Physician and Leadership Solutions and Technology and Workforce Solutions as elective procedures resume.
  • SG&A has decreased by approximately 15% on an annualized basis from pre-COVID-19 run rate.

Challenges Ahead

  • Stay-at-home orders and suspension of elective procedures have caused a material decrease in healthcare utilization.
  • Buying decisions from clients have been delayed.
  • Recent travel nurse demand has fallen significantly.
  • Trajectory of volume and revenue is declining through the quarter for Nurse and Allied Solutions segment.
  • Volumes for nurse, allied and revenue cycle are expected to be below prior year in June.